Aktis Oncology, Inc. (AKTS) · Aug 13, 2026 · Earnings

Pipeline moves forward—but the quarter’s loss looks heavier than expected

Miss — Q2 net loss $24.1M; published EPS consensus indicated roughly $0.25 loss

Aktis advanced two radiopharmaceutical programs and extended its runway, but rising expenses likely drove a quarterly loss below consensus.

The financial result appears to have missed a thin consensus. Published estimates from two analysts pointed to an average Q2 loss of roughly $0.25 per share, while the filing reports a $24.1 million net loss for the quarter; the filing does not provide quarterly EPS. Collaboration revenue of $3.4 million was ahead of the roughly $2.0 million published revenue expectation, but revenue is not the main valuation driver for this clinical-stage biotech.

MetricQ2 2026Q2 2025Market comparison
Collaboration revenue$3.4M$1.6MAbove published revenue expectation of roughly $2.0M
R&D expense$25.3M$18.6MHigher as trials advance
G&A expense$7.0M$3.9MHigher public-company and hiring costs
Net loss$24.1M$18.1MLoss widened materially
Cash, equivalents and marketable securities$517.3M$226.8M at Dec. 31, 2025Runway stated into 2029

The pipeline delivered execution, not a major surprise. AKY-2519 produced first-in-human imaging and dosimetry data at ASCO, its prostate Phase 1b trial is enrolling, and regulators cleared the broader BActinium-2 basket trial. Those developments expand the program’s potential, but the ASCO data and the second-half-2026 basket-trial start were already part of the standing narrative rather than newly revealed evidence of efficacy. (AKY-2519 highlights) (Anticipated milestones for the next 12 months)

Cash removes near-term financing pressure but does not erase spending risk. Cash rose to $517.3 million after the January 2026 IPO and is expected to fund operations into 2029. That is a meaningful balance-sheet positive, but quarterly R&D rose 36% year over year and the net loss widened by $6.0 million as both clinical development and corporate infrastructure scaled. (Balance Sheet Data) (Condensed Consolidated Statement of Operations)

Net read: operationally on track, financially worse than expected. The company reaffirmed its development timetable and added no clinical setback, but those positives were largely anticipated. Against the market’s earnings benchmark, the heavier loss is the clearest new signal, making this a modest earnings miss rather than a clean execution beat.

What to watch next

BActinium-2 basket trial initiation, second half of 2026

Original filing on SEC EDGAR

Pipeline moves forward—but the quarter’s loss looks heavier than expected | AKTS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.